PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders

Table 3 Florbenazine SUVR by Clinical Diagnosis for each striatal region

	HC	PD	AD	DLB	P value	Pair-wise comparison
Whole striatum*	2.84 (0.552)	1.72 (0.172)	3.04 (0.579)	1.87 (0.372)	0.0001	a, c, d, f
Caudate	2.60(0.529)	1.77 (0.415)	2.21 (0.458)	1.79 (0.418)	0.0303	c, f
Anterior putamen	2.98 (0.601)	1.86 (0.084)	3.39 (0.744)	2.05 (0.519)	0.0003	a, c, d, f
Posterior putamen	2.93 (0.529)	1.53 (0.104)	3.52 (0.758)	1.78 (0.400)	<0.0001	a, c, d, f
Lower posterior putamen**	2.82 (0.474)	1.46 (0.120)	3.41 (0.753)	1.67 (0.427)	<0.0001	a, c, d, f
Laterality index***	0.94 (0.029)	0.91 (0.043)	0.94 (0.032)	0.88 (0.105)	0.5582
Caudate/putamen ratio****	0.88 (0.035)	1.15 (0.240)	0.64 (0.151)	1.03 (0.240)	0.0011	b, d, f

*Average of left and right caudate, anterior putamen and posterior putamen.
**Posterior putamen with lower SUVr for each subject.
***Ratio of lower to higher posterior putamen for each subject. A higher value indicates greater asymmetry.
****Ratio of average caudate (left and right) to average posterior putamen (left and right). A higher value indicates greater difference between the caudate and posterior putamen.
Mean SUVr values (and SD) are given for each group. P-values are for the overall group comparison from Kruskal-Wallis test. Subsequent pair-wise comparisons are noted by the letters in the last column if the overall comparison was significant (p value < 0.05; a = HC vs. PD; b = HC vs. AD; c = HC vs. DLB; d = PD vs. AD; e = PD vs. DLB; f = AD vs. DLB).

ISSN: 1471-2377